WO2000045176A3 - VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP - Google Patents

VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP Download PDF

Info

Publication number
WO2000045176A3
WO2000045176A3 PCT/EP2000/000602 EP0000602W WO0045176A3 WO 2000045176 A3 WO2000045176 A3 WO 2000045176A3 EP 0000602 W EP0000602 W EP 0000602W WO 0045176 A3 WO0045176 A3 WO 0045176A3
Authority
WO
WIPO (PCT)
Prior art keywords
terminal probnp
identifying
probnp
terminal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/000602
Other languages
English (en)
French (fr)
Other versions
WO2000045176A2 (de
Inventor
Johann Karl
Helmut Lill
Peter Stahl
Kerstin Krueger
Anneliese Borgya
Andreas Gallusser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2001123936/14A priority Critical patent/RU2218568C2/ru
Priority to CNB008032343A priority patent/CN1327228C/zh
Priority to CA002359667A priority patent/CA2359667C/en
Priority to DE50014666T priority patent/DE50014666D1/de
Priority to PL364798A priority patent/PL204235B1/pl
Priority to HU0105195A priority patent/HU228625B1/hu
Priority to JP2000596377A priority patent/JP3987284B2/ja
Priority to EP00903642A priority patent/EP1151304B9/de
Priority to DK06010440T priority patent/DK1698901T3/da
Priority to AU25451/00A priority patent/AU758562B2/en
Priority to IL14406200A priority patent/IL144062A0/xx
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Priority to NZ512762A priority patent/NZ512762A/xx
Priority to DK00903642T priority patent/DK1151304T3/da
Priority to CN2007101051759A priority patent/CN101046478B/zh
Publication of WO2000045176A2 publication Critical patent/WO2000045176A2/de
Priority to IL144062A priority patent/IL144062A/en
Publication of WO2000045176A3 publication Critical patent/WO2000045176A3/de
Priority to NO20013698A priority patent/NO329866B1/no
Priority to ZA200106193A priority patent/ZA200106193B/en
Anticipated expiration legal-status Critical
Priority to US11/500,555 priority patent/US20070059767A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Seasonings (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of Radiation (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zum Nachweis von N-terminalem proBNP in einer Probe mit mindestens zwei Antikörpern, die verschiedene Epitope des N-terminalen proBNP erkennen. Das Verfahren kann zur Differenzierung bzw. Klassifizierung von Proben von Gesunden und Proben von Patienten der NYHA-Klassen I bis IV angewendet werden. Ausserdem betrifft die Erfindung rekombinantes N-terminales proBNP, dessen Verwendung als Standard in einem Verfahren zum Nachweis von N-terminalem proBNP, sowie Antikörper, die rekombiantes N-terminales proBNP erkennen, und deren Herstellung.
PCT/EP2000/000602 1999-01-29 2000-01-27 VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP Ceased WO2000045176A2 (de)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IL14406200A IL144062A0 (en) 1999-01-29 2000-01-27 METHOD OF IDENTIFYING N-TERMINAL proBNP
CA002359667A CA2359667C (en) 1999-01-29 2000-01-27 Method of identifying n-terminal probnp
DE50014666T DE50014666D1 (de) 1999-01-29 2000-01-27 VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP
PL364798A PL204235B1 (pl) 1999-01-29 2000-01-27 Sposób wykrywania natywnego N-końcowego proBNP, zastosowanie tego sposobu, zastosowanie zrekombinowanego N-końcowego proBNP, przeciwciała przeciw zrekombinowanemu N-końcowemu proBNP, linie komórkowe i sposoby wytwarzania przeciwciał poliklonalnych i monoklonalnych
HU0105195A HU228625B1 (en) 1999-01-29 2000-01-27 Method of identifying n-terminal probnp
JP2000596377A JP3987284B2 (ja) 1999-01-29 2000-01-27 Ｎ末端ｐｒｏＢＮＰの同定方法
NZ512762A NZ512762A (en) 1999-01-29 2000-01-27 Method of identifying N-terminal proBNP (brain natriuretic peptide) using antibodies
CNB008032343A CN1327228C (zh) 1999-01-29 2000-01-27 鉴定样品中的n－末端前bnp的方法
AU25451/00A AU758562B2 (en) 1999-01-29 2000-01-27 Method of identifying N-terminal proBNP
RU2001123936/14A RU2218568C2 (ru) 1999-01-29 2000-01-27 Способ обнаружения n-концевого про-мнп
DK06010440T DK1698901T3 (da) 1999-01-29 2000-01-27 Metode til at detektere N-terminalt proBNP
EP00903642A EP1151304B9 (de) 1999-01-29 2000-01-27 VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP
DK00903642T DK1151304T3 (da) 1999-01-29 2000-01-27 Fremgangsmåde til påvisning af N-terminalt proBNP
CN2007101051759A CN101046478B (zh) 1999-01-29 2000-01-27 鉴定样品中的n-末端前bnp的方法
IL144062A IL144062A (en) 1999-01-29 2001-06-28 Method for identifying N-terminal proBNP
NO20013698A NO329866B1 (no) 1999-01-29 2001-07-27 Fremgangsmate for pavisning av nativt N-terminalt proBNP i en prove som utfores i "sandwich"-format ved anvendelse av minst to antistoffer som gjenkjenner forskjellige epitoper i det native N-terminale proBNP, og som samtidig kan bindes til nativt N-terminalt proBNP, anvendelse av fremgangsmaten for differensiering mellom prover, anvendelse av rekombinant N-terminalt proBNP som standard i en fremgangsmate, antistoffer mot N-terminalt proBNP fremstilt ved immunisering av en egnet organisme med rekombinant fremstilt N-terminalt proBNP, samt cellelinje.
ZA200106193A ZA200106193B (en) 1999-01-29 2001-07-27 Method of identifying N-terminal proBNP.
US11/500,555 US20070059767A1 (en) 1999-01-29 2006-08-07 Method of identifying N-terminal proBNP

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19903489 1999-01-29
DE19903489.3 1999-01-29
DE19911044.1 1999-03-12
DE19911044 1999-03-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/500,555 Continuation US20070059767A1 (en) 1999-01-29 2006-08-07 Method of identifying N-terminal proBNP

Publications (2)

Publication Number Publication Date
WO2000045176A2 WO2000045176A2 (de) 2000-08-03
WO2000045176A3 true WO2000045176A3 (de) 2001-07-26

Family

ID=26051550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000602 Ceased WO2000045176A2 (de) 1999-01-29 2000-01-27 VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP

Country Status (21)

Country Link
US (1) US20070059767A1 (de)
EP (2) EP1151304B9 (de)
JP (1) JP3987284B2 (de)
KR (1) KR100572542B1 (de)
CN (2) CN101046478B (de)
AT (2) ATE403158T1 (de)
AU (1) AU758562B2 (de)
CA (1) CA2359667C (de)
CY (1) CY1108450T1 (de)
DE (2) DE50015291D1 (de)
DK (2) DK1698901T3 (de)
ES (2) ES2312062T3 (de)
HU (1) HU228625B1 (de)
IL (2) IL144062A0 (de)
NO (1) NO329866B1 (de)
NZ (1) NZ512762A (de)
PL (1) PL204235B1 (de)
PT (1) PT1698901E (de)
RU (1) RU2218568C2 (de)
WO (1) WO2000045176A2 (de)
ZA (1) ZA200106193B (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691587B2 (en) 2008-04-30 2014-04-08 Roche Diagnostics Operations, Inc. Use of SFRP-3 in the assessment of heart failure
US9267954B2 (en) 2007-03-08 2016-02-23 The Governing Council Of The University Of Toronto Use of SLIM-1 in the assessment of heart failure
US10488422B2 (en) 2007-01-25 2019-11-26 Roche Diagnostics Operations, Inc. Use of IGFBP-7 in the assessment of heart failure

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03004105A (es) 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
FR2843396B1 (fr) * 2002-08-07 2005-04-15 Bio Rad Pasteur Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
US6960472B2 (en) * 2002-11-18 2005-11-01 Ottawa Heart Institute Research Corporation Monoclonal antibodies against N-Terminus proBNP
US20050287613A1 (en) * 2002-11-18 2005-12-29 George Jackowski Polyclonal-polyclonal ELISA assay for detecting N-terminus-proBNP
EP1562990B1 (de) 2002-11-18 2010-07-21 Syn X Pharma, Inc. Polyklonaler-monoklonaler-elisa-assay zum nachweis von n-terminalem probnp
US20040096919A1 (en) 2002-11-18 2004-05-20 Michelle Davey Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP
WO2004046181A1 (de) * 2002-11-20 2004-06-03 B.R.A.H.M.S Aktiengesellschaft Sandwich-immunoassay zur bestimmung bon proanp-teilpeptiden
US7767419B2 (en) * 2003-02-04 2010-08-03 Nexus Dx, Inc. Calibrator for NT-proBNP immunoassay
CN100497393C (zh) 2003-05-12 2009-06-10 霍夫曼-拉罗奇有限公司 用结合脑钠尿肽前体分子氨基酸41-46的单克隆抗体检测脑钠尿肽前体分子的方法
GB2403533A (en) 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
DE10355731A1 (de) 2003-11-28 2005-06-30 Roche Diagnostics Gmbh Analytischer Sandwichtest zur Bestimmung von NT-proBNP
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
AT500800B1 (de) * 2004-09-08 2008-07-15 Biomedica Medizinprodukte Gmbh Verfahren zur bestimmung von probnp
FR2863269B1 (fr) * 2005-01-14 2006-05-26 Bio Rad Pasteur Peptides specifiques pour le diagnostic de l'insuffisance cardiaque
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
EP1722232A1 (de) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion
EP1909207B1 (de) * 2006-09-11 2015-03-04 F.Hoffmann-La Roche Ag Messbereichserweiterung chromatografischer Schnellteste
EP1909206A1 (de) 2006-09-11 2008-04-09 Roche Diagnostics GmbH Messbereichserweiterung chromatografischer Schnellteste
DE102006060835A1 (de) * 2006-12-22 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung des akuten Koronarsyndroms mittels CT-proET-1 in Kombination mit NT-proBNP
EP1970709B1 (de) * 2007-03-06 2013-07-10 Roche Diagnostics GmbH Verwendung von Peptiden vom Typ BNP zur Vorhersage des Dialysebedarfs
JP5198565B2 (ja) * 2007-08-30 2013-05-15 エフ．ホフマン−ラ ロシュ アーゲー 心疾患に関連する又は関連しないｇｄｆ−１５の上昇の区別のための手段及び方法
CN102549436A (zh) 2009-07-27 2012-07-04 霍夫曼-拉罗奇有限公司 mimecan在评价心力衰竭中的用途
EP2478367B2 (de) 2009-09-14 2018-04-04 Koninklijke Philips N.V. Hochsensitiver Immunoassay mit grossen Partikelmarkern
CN101819205A (zh) * 2010-06-03 2010-09-01 中国人民解放军第三军医大学 人n端b型利钠肽原免疫分析试剂盒及其制备方法
US8778699B2 (en) * 2010-08-04 2014-07-15 Idexx Laboratories, Inc. Detection of degradation products of canine NT-proBNP
AU2012262154B2 (en) 2011-05-31 2016-08-04 Idexx Laboratories, Inc. Detection of degradation products of feline NT-proBNP
CN102692512A (zh) * 2012-06-26 2012-09-26 南京基蛋生物科技有限公司 NT-proBNP双抗夹心快速检测试剂盒
CN109678958B (zh) * 2019-01-31 2022-03-18 重庆探生科技有限公司 一种人NT-proBNP特异性重组羊单克隆抗体及其制备方法和应用
EP4014041A1 (de) 2019-08-13 2022-06-22 Gentian AS Hochempfindliches partikelverstärktes assay zur quantifizierung von nt-probnp
EP4409297B1 (de) 2021-10-01 2025-01-29 Gentian AS Neues verfahren zur bestimmung einer konzentration von n-terminalem pro-hormon-bnp (nt-probnp) in einer probe

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024531A1 (en) * 1992-06-03 1993-12-09 Medinnova Sf Bnp antibody and immunoassay using it

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496654A (en) * 1983-04-08 1985-01-29 Quidel Detection of HCG with solid phase support having avidin coating
US4737453A (en) * 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
DE3509958A1 (de) * 1985-03-20 1986-09-25 Bayer Ag, 5090 Leverkusen Monoklonale antikoerper gegen atriale, natriuretische peptide vom menschen
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
WO2008091207A1 (en) * 2007-01-26 2008-07-31 Telefonaktiebolaget Lm Ericsson (Publ) Border region processing in images

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024531A1 (en) * 1992-06-03 1993-12-09 Medinnova Sf Bnp antibody and immunoassay using it

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAGGUBATI, S. ET AL.: "Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators", CARDIOVASCULAR RESEARCH, vol. 36, 1997, pages 246 - 255, XP000913576 *
HUNT P J ET AL: "IMMUNOREACTIVE AMINO-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-PROBNP): A NEW MARKER OF CARDIAC IMPAIRMENT", CLINICAL ENDOCRINOLOGY,GB,BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, vol. 47, 1997, pages 287 - 296, XP000913471, ISSN: 0300-0664 *
HUNT P J ET AL: "THE AMINO-TERMINAL PORTION OF PRO-BRAIN NATRIURETIC PEPTIDE (PRO-BNP) CIRCULATES IN HUMAN PLASMA", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 214, no. 3, 1995, pages 1175 - 1183, XP000907386, ISSN: 0006-291X *
HUNT P J ET AL: "THE ROLE OF THE CIRCULARION IN PROCESSING PRO-BRAIN NATRIURETIC PEPTIDE (PROBNP) TO AMINO-TERMINAL BNP AND BNP-32", PEPTIDES,US,ELMSFORD, vol. 18, no. 10, 1997, pages 1475 - 1481, XP000913698, ISSN: 0196-9781 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10488422B2 (en) 2007-01-25 2019-11-26 Roche Diagnostics Operations, Inc. Use of IGFBP-7 in the assessment of heart failure
US10996229B2 (en) 2007-01-25 2021-05-04 Roche Diagnostics Operations, Inc. Use of IGFBP-7 in the assessment of heart failure
US9267954B2 (en) 2007-03-08 2016-02-23 The Governing Council Of The University Of Toronto Use of SLIM-1 in the assessment of heart failure
US8691587B2 (en) 2008-04-30 2014-04-08 Roche Diagnostics Operations, Inc. Use of SFRP-3 in the assessment of heart failure

Also Published As

Publication number Publication date
CN1339107A (zh) 2002-03-06
JP3987284B2 (ja) 2007-10-03
EP1698901B1 (de) 2008-07-30
ES2312062T3 (es) 2009-02-16
CN1327228C (zh) 2007-07-18
KR20010101874A (ko) 2001-11-15
DE50015291D1 (de) 2008-09-11
CA2359667A1 (en) 2000-08-03
PL364798A1 (en) 2004-12-13
PL204235B1 (pl) 2009-12-31
EP1698901A1 (de) 2006-09-06
ATE403158T1 (de) 2008-08-15
AU2545100A (en) 2000-08-18
CY1108450T1 (el) 2014-04-09
WO2000045176A2 (de) 2000-08-03
DK1698901T3 (da) 2008-12-08
AU758562B2 (en) 2003-03-27
HU228625B1 (en) 2013-04-29
HUP0105195A2 (hu) 2002-04-29
IL144062A (en) 2007-09-20
NO20013698D0 (no) 2001-07-27
ZA200106193B (en) 2002-05-02
EP1151304B9 (de) 2008-06-04
NZ512762A (en) 2003-02-28
ATE373826T1 (de) 2007-10-15
HUP0105195A3 (en) 2005-11-28
DK1151304T3 (da) 2008-01-28
DE50014666D1 (de) 2007-10-31
IL144062A0 (en) 2002-04-21
US20070059767A1 (en) 2007-03-15
NO329866B1 (no) 2011-01-17
EP1151304A2 (de) 2001-11-07
PT1698901E (pt) 2008-10-08
CA2359667C (en) 2009-10-20
RU2218568C2 (ru) 2003-12-10
ES2292426T3 (es) 2008-03-16
CN101046478B (zh) 2013-04-03
CN101046478A (zh) 2007-10-03
NO20013698L (no) 2001-09-28
KR100572542B1 (ko) 2006-04-24
EP1151304B1 (de) 2007-09-19
JP2003508724A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
WO2000045176A3 (de) VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP
EP2053408A3 (de) Prozedur zur strukturellen Charakterisierung rekombinanter polyclonaler Proteine oder einer polyclonalen Zelllinie
WO2004025248A3 (en) Antibody pair screening methods
WO2001061305A3 (en) Immunoassays detecting or making use of at least two rubber latexallergens
DE10082504D2 (de) Indikatorpeptid zur Diagnose und/oder Vorhersage von cardiovasculären und /oder endothelialen Erkrankungen, Antikörperzusammensetzung und immunoassay
WO2002065126A3 (en) Use of troponin i as a species marker protein for meat speciation in both raw and heat-processed products
WO2000026251A3 (en) A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
AU2002233800A1 (en) Method and kit for predicting cancer
WO1999000671A3 (en) Method for identification of tumor antigens with autoantibodies in serum
EP0738735A3 (de) Typ I Prokollagen aminoterminales Propeptid, dessen Antikörper und Testverfahren unter Verwendung davon
WO1998029726A3 (en) Method of detecting and determining the concentration of total troponin i in a biological sample
WO2000078802A3 (en) Secreted polypeptides and corresponding polynucleotides
ATE184286T1 (de) Hgpiib-fragmente und ihre verwendung in in-vitro- verfahren zur bestimmung von in vivo stattfindenden thrombotischen ereignissen
WO2004113566A3 (en) Disease related protein network
IL165776A0 (en) Methods and compositions for modulating and detecting wisp activity
AU2003225900A1 (en) Antibody disulfide isomers, use thereof, and methods of analyzing same
WO2004015082A3 (en) Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
Pan et al. NT-proBNP concentration in Chinese apparently healthy individuals
WO2000047610A3 (en) Method for altering undesirable immune responses to polypeptides
WO1998047922A3 (en) Determination of recombinant glycosylated proteins and peptides in biological fluids
Tanaka et al. Novel and sensitive noncompetitive enzyme immunoassay to measure peptides by biotinylation
Zou et al. The levels of interleukin 8 in gingival crevicular fluids of chronic periodontitis
DE60045915D1 (de) Humanes und maus trek-1 kaliumkanal protein und dessen verwendung
WO2000071747A3 (de) Erkennungssystem zur auftrennung von probenbestandteilen, seine herstellung und verwendung
WO2000017658A3 (en) Diagnosis of myocardial disease or stroke using factor ix activation peptide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00803234.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN HU IL JP KR MX NO NZ PL RU US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000903642

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 25451/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 144062

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 512762

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2359667

Country of ref document: CA

Ref document number: 2359667

Country of ref document: CA

Kind code of ref document: A

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN HU IL JP KR MX NO NZ PL RU US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2000 596377

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/06193

Country of ref document: ZA

Ref document number: PA/a/2001/007637

Country of ref document: MX

Ref document number: 200106193

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020017009587

Country of ref document: KR

Ref document number: 1020017009576

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000903642

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017009587

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09890442

Country of ref document: US

WWR Wipo information: refused in national office

Ref document number: 1020017009576

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020017009576

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 25451/00

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017009587

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2000903642

Country of ref document: EP